AUTH/3632/4/22 - Complainant v Daiichi Sankyo

Allegations about a Lixiana webinar

  • Received
    11 April 2022
  • Case number
  • Applicable Code year
  • Completed
    03 April 2023
  • No breach Clause(s)
  • Additional sanctions
  • Appeal
    No appeal

Case Summary

This case was in relation to a promotional video on how to initiate Lixiana (edoxaban) on a learned society’s website.

The Panel ruled no breach of the following Clauses of the 2021 Code because on the evidence available before it the material had not been made available to health professionals and was draft content, on what appeared to be an unlisted staging site:

No Breach of Clause 2

Requirement that activities or material must not bring discredit upon, or reduce confidence in, the pharmaceutical industry

No Breach of Clause 5.1

Requirement to maintain high standards

No Breach of Clause 6.1

Requirement that information must be accurate, up-to-date and not misleading

No Breach of Clause 6.2

Requirement that claims/information/comparisons must be capable of substantiation

No Breach of Clause 8.1

Requirement to certify promotional material

This summary is not intended to be read in isolation.
For full details, please see the full case report below.